Skip to content

ASPIRE BIOPHARMA HOLDINGS, INC.: 10-Q filed 2024-11-14

What ASPIRE BIOPHARMA HOLDINGS, INC. reported in its quarterly report filed 2024-11-14 (fiscal Q3 2024): 18 published measures, 54 facts as tagged in accession 0001493152-24-045850.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-14
Fiscal period
fiscal Q3 2024
Accession
0001493152-24-045850 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ASPIRE BIOPHARMA HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-306,663,166USD
At 2023-12-3119,982,392USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-306,572,881USD
At 2023-12-31403,328USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-30-6,511,072USD
At 2024-06-30-5,897,307USD
At 2024-03-31-2,567,806USD
At 2023-12-31-322,105USD
At 2023-09-30-62,954USD
At 2023-06-30261,788USD
At 2023-03-31-10,262,466USD
At 2022-12-31-9,937,901USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-537,019USD92
2024-01-01 to 2024-09-30-3,606,378USD274
2024-04-01 to 2024-06-30-602,258USD91
2024-01-01 to 2024-03-31-2,467,101USD91
2023-07-01 to 2023-09-30-69,258USD92
2023-01-01 to 2023-09-304,614,991USD273
2023-04-01 to 2023-06-301,811,817USD91
2023-01-01 to 2023-03-312,872,433USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-2,826,804USD274
2023-01-01 to 2023-09-30-496,979USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-10,954,519USD274
2023-01-01 to 2023-09-30-284,916,127USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-09-3013,781,323USD274
2023-01-01 to 2023-09-30284,916,127USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-15,375,643USD
At 2023-12-31-11,287,754USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-3061,809USD
At 2023-12-3181,223USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-306,572,881USD
At 2023-12-31403,328USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2024-01-01 to 2024-09-3013,781,323USD274
2023-01-01 to 2023-09-30284,916,127USD273

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-30630,772USD92
2024-01-01 to 2024-09-303,654,462USD274
2023-07-01 to 2023-09-30324,742USD92
2023-01-01 to 2023-09-30937,554USD273

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-09-30280USD
At 2022-12-31497,259USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-308,863,852USD
At 2023-12-3110,964,930USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-09-3036,775USD
At 2023-12-3181,223USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30630,772USD92
2024-01-01 to 2024-09-303,654,462USD274
2023-07-01 to 2023-09-30324,742USD92
2023-01-01 to 2023-09-30937,554USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-07-01 to 2024-09-3025,503USD92
2024-01-01 to 2024-09-30-33,437USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2024-09-3093,753USD92
2024-01-01 to 2024-09-3048,084USD274
2023-07-01 to 2023-09-30255,484USD92
2023-01-01 to 2023-09-305,552,545USD273

Inspect the source

Entity
ASPIRE BIOPHARMA HOLDINGS, INC. / CIK 0001847345
Captured
2026-09-21T17:32:16.061Z
SEC response SHA-256
40d6d0e6731934d6542812e865819d815a2e8f7284c4e26de8ab491caca2a549

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001847345.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))